Evidence map›Paper›PMID 26860528›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2016

Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

David B Granet, Nickisa Hodgson, Kyle J Godfrey, Ricardo Ventura, Don O Kikkawa, Leah Levi, Michael Kinori

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Teprotumumab for Thyroid Eye Disease-related Strabismus.Ophthalmic plastic and reconstructive surgery
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

David B GranetDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA. dgranet@ucsd.edu.
Nickisa HodgsonDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA.
Kyle J GodfreyDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA.
Ricardo VenturaDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA.
Don O KikkawaDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA.
Leah LeviDivision of Ophthalmology, Scripps Clinic, La Jolla, CA, USA.
Michael KinoriDepartment of Ophthalmology and The Thyroid Eye Center, University of California, San Diego, CA, USA.
University of California, San Diego · USScripps Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid eye disease (TED) presents a management dilemma for strabismologists due to the variability of its clinical course. Prisms may be prescribed to relieve diplopia in small deviations. Surgical intervention, on the other hand, should not be done until the active phase of the disease has subsided. We report our experience with chemodenervation utilizing botulinum toxin (BT) injection in the management of TED-related strabismus.

methodsA retrospective chart review was done on twenty-two (22) consecutive patients receiving BT injections at the University of California, San Diego (UCSD) Thyroid Eye Center. All BT injections were administered by a single physician under electromyographic guidance.

resultsThe clinical records of 22 patients (18 females) were reviewed. Seven patients (32 %) had a reduction of their deviation to a point where surgery was not required. In six patients (27 %), surgery was required but an improvement in ocular deviation was found, altering the original surgical plan. In four patients (18 %), the deviation continued to progress after BT injection. Success rates were higher if pre-treatment deviation was less than 20 prism diopters ((∆)).

conclusionOne third of the chemodenervation-treated patients avoided surgical intervention, with an additional 27 % (total of 40 % of those who needed surgery) having a reduced deviation prior to surgery. Using BT injection to extraocular muscles to treat diplopia in TED patients is most effective in preventing surgery in those patients with 20(∆) or less of deviation.

Indexed as

Botulinum Toxins, Type ANerve BlockAdultAgedAged, 80 and overElectromyographyFemaleGraves OphthalmopathyHumansInjections, IntramuscularMaleMiddle AgedOculomotor MusclesRetrospective StudiesStrabismusBotulinum Toxins, Type ABotulinum toxinRestrictive strabismusStrabismus surgeryThyroid eye disease

Identifiers

PMID26860528
OpenAlexW2265458028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.